Reply to K. Takada et al
| dc.contributor.author | Sharafeldin, Noha | |
| dc.contributor.author | Bates, Benjamin | |
| dc.contributor.author | Song, Qianqian | |
| dc.contributor.author | Madhira, Vithal | |
| dc.contributor.author | Shao, Yu Raymond | |
| dc.contributor.author | Liu, Feifan | |
| dc.contributor.author | Bergquist, Timothy | |
| dc.contributor.author | Su, Jing | |
| dc.contributor.author | Topaloglu, Umit | |
| dc.contributor.department | Biostatistics, School of Public Health | |
| dc.date.accessioned | 2023-10-09T12:06:22Z | |
| dc.date.available | 2023-10-09T12:06:22Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | See the letter "Reasons to Consider the COVID-19 Vaccination Status of Patients With Cancer When Analyzing Their COVID-19 Outcomes" in volume 39 on page 3996. | |
| dc.eprint.version | Final published version | |
| dc.identifier.citation | Sharafeldin N, Bates B, Song Q, et al. Reply to K. Takada et al. J Clin Oncol. 2021;39(35):3997-3998. doi:10.1200/JCO.21.02150 | |
| dc.identifier.uri | https://hdl.handle.net/1805/36214 | |
| dc.language.iso | en_US | |
| dc.publisher | American Society of Clinical Oncology | |
| dc.relation.isversionof | 10.1200/JCO.21.02150 | |
| dc.relation.journal | Journal of Clinical Oncology | |
| dc.rights | Publisher Policy | |
| dc.source | PMC | |
| dc.subject | COVID-19 vaccination | |
| dc.subject | Cancer patients | |
| dc.subject | National COVID Cohort Collaborative | |
| dc.title | Reply to K. Takada et al | |
| dc.type | Article | |
| ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659995/ |